Skip to main content
CYIGinactive

SPRING PHARMACEUTICAL GROUP, INC.

·CEO: Tinghe Yan

CYIG evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for CYIG—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

10.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

—

Next Catalyst

—

Financial data as of Dec 31, 2018.

Tracking 28 clinical trials for SPRING PHARMACEUTICAL GROUP, INC..

Run SPRING PHARMACEUTICAL GROUP, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available SPRING PHARMACEUTICAL GROUP, INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health9.9

D/E 0.05

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Governance

Run my thesis on this company
925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.